Quoin Pharmaceuticals Ltd.: STEMPOINT CAPITAL LP discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Stempoint Capital LP disclosed a stake of more than 5% in Quoin Pharmaceuticals Ltd. via a Schedule 13G filing with the SEC (accession 0001104659-26-127778). The filing signals that the investor has crossed the 5% beneficial ownership threshold, making it a reportable holder under SEC rules. The exact number of shares and percentage held were not specified in the headline disclosure. Investors will watch for further detail in the full filing and any subsequent 13G amendments that clarify the size and nature of the position.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
STEMPOINT CAPITAL LP, Quoin Pharmaceuticals Ltd.